← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Geron Corporation
Menlo Park, CA
$15,000
Total funding
4
Grants
Funding mix
By agency
NIH$15,000 · 4
By mechanism
R13$15,000 · 1
U19$0 · 3
Investigators at Geron Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
TELOMERASE: A MOLECULAR TARGET FOR CANCER THERAPY$796,189
U19 · FY2002 · CA
TELOMERASE: A MOLECULAR TARGET FOR CANCER THERAPY$632,753
U19 · FY2001 · CA
TELOMERASE--A MOLECULAR TARGET FOR CANCER THERAPY$605,355
U19 · FY2000 · CA
TELOMERASE: A MOLECULAR TARGET FOR CANCER THERAPY$248,642
U19 · FY2003 · CA
TELOMERASE AND TELOMERE DYNAMICS IN CANCER AND AGING$15,000
R13 · FY2000 · AG
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$0
U19 · FY2000 · CA
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$0
U19 · FY2002 · CA
ADAPTIVE IMMUNOTHERAPY WITH LONG CIRCULATING MACROMOLECULAR THERAPEUTICS$0
U19 · FY2001 · CA
PRECLINICAL EVALUATION OF MACROMOLECULAR THERAPEUTICS$0
U19 · FY2002 · CA
ADAPTIVE IMMUNOTHERAPY WITH LONG CIRCULATING MACROMOLECULAR THERAPEUTICS$0
U19 · FY2000 · CA
ADAPTIVE IMMUNOTHERAPY WITH LONG CIRCULATING MACROMOLECULAR THERAPEUTICS$0
U19 · FY2002 · CA
PRECLINICAL EVALUATION OF MACROMOLECULAR THERAPEUTICS$0
U19 · FY2000 · CA
PRECLINICAL EVALUATION OF MACROMOLECULAR THERAPEUTICS$0
U19 · FY2001 · CA
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY$0
U19 · FY2001 · CA